Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: a prospective exploratory imaging study

Conclusions: The 68Ga-FAPi-46 PET biodistribution across multiple cancers reflects FAP expression as determined by IHC. This translational validation paves the way for large scale prospective trials on the use of 68Ga-FAPi-46 PET/CT as a biomarker and stratification tool for FAP-targeted therapies.

Source: Journal of Nuclear Medicine - May 18, 2021 Category: Nuclear Medicine Authors: Mona, C., Benz, M., Hikmat, F., Grogan, T., Lueckerath, K., Razmaria, A. A., Riahi, R., Slavik, R., Grigis, M., Carlucci, G., Kelly, K., Czernin, J., Dawson, D., Calais, J. Tags: Technical Advances in Clinical Assessment of Solid Tumors Source Type: research